Answers are grounded in this paper and cite their sources.
The efficacy of adoptive cell therapies depends on the presence of T cells with durable self-renewal, proliferative capacity, and differentiation potential, yet heterogeneity within starting cell populations remains a major barrier to consistent clinical outcomes. Here, we identify CD49f as a marker of a unique subset of human memory T cells with stem-like characteristics. CD49f Hi memory CD8 + and CD4 + T cells exhibited transcriptional and phenotypic features associated with T cell stemness, including elevated LEF1, TCF1, CCR7, CD27, and CD28, while CD49f Lo cells exhibited effector-like transcriptional programs. Clinical evaluation of solid-organ transplant recipients treated with virus-specific T cells for cytomegalovirus complications demonstrated that autologous T cell therapies manufactured from CD49f Hi -enriched T cells were associated with superior immune reconstitution and greater in vivo expansion of CMV-specific T cells. Functional assays further revealed that CD49f Hi memory T cells possessed enhanced proliferative capacity and transcriptional plasticity following activation. Consistent with these findings, CD19 CAR T cells engineered from CD49f Hi memory T cells demonstrated improved persistence and conferred superior survival in a preclinical lymphoma model. Together, these findings establish CD49f as a marker of a stem-like memory T cell subset with enhanced therapeutic potential and identify CD49f Hi enrichment as a practical strategy to improve the consistency, durability, and clinical efficacy of both virus-specific and CAR T cell therapies.
No takes yet. Share an insight, caveat, or question.
Lineburg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: